GEODE CAPITAL MANAGEMENT, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 95 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2020. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$27,535,077
-15.9%
1,000,425
+3.7%
0.00%
-25.0%
Q2 2023$32,744,937
-1.7%
965,073
+4.3%
0.00%0.0%
Q1 2023$33,306,986
+84480.6%
925,708
+4.8%
0.00%
-33.3%
Q4 2022$39,379
-99.8%
883,535
+3.6%
0.01%
+50.0%
Q3 2022$23,969,000
+5.7%
852,706
+1.4%
0.00%
+33.3%
Q2 2022$22,676,000
-22.2%
841,124
-1.7%
0.00%
-25.0%
Q1 2022$29,138,000
-6.9%
855,513
+5.6%
0.00%0.0%
Q4 2021$31,314,000
-26.8%
810,420
+2.3%
0.00%
-33.3%
Q3 2021$42,787,000
+90.1%
792,507
+17.8%
0.01%
+100.0%
Q2 2021$22,503,000
+209.7%
672,948
+90.8%
0.00%
+200.0%
Q1 2021$7,265,000
+38.7%
352,697
+17.9%
0.00%0.0%
Q4 2020$5,239,000
+37.1%
299,054
+16.1%
0.00%0.0%
Q3 2020$3,820,000
+125.6%
257,629
+97.8%
0.00%
Q2 2020$1,693,000
+884.3%
130,237
+25.2%
0.00%
Q1 2020$172,000
-62.8%
103,983
-50.0%
0.00%
Q4 2019$462,000
+111.0%
207,966
+101.5%
0.00%
Q3 2019$219,000
-20.7%
103,1930.0%0.00%
Q2 2019$276,000
-48.1%
103,193
-4.7%
0.00%
Q1 2019$532,000108,3050.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2020
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders